Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$13.02M$13.02Mderived+9.7% vs Q4 2024 Net Income-$31.86M-$31.86MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$28,839,000N/M Operating Cash Flowderived-$8,469,000N/M Free Cash Flowderived-$8,554,000N/M Margins · derivedOperating margin-221.6%−107.2 pt vs Q4 2024
Net margin-244.8%−101.1 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 4, 2026 · 63 d after period end